Felip et al.22 demonstrated that using atezolizumab as adjuvant therapy for patients with stage II to IIIA NSCLC improves the PFS rates of patients expressing PD-L1 in ≥ 1% of tumour cells (HR = 0.66, 95% CI = 0.50–0.88, p = 0.0039) compared with those of patients receiving the best supportive care (IMpower 010 study). Here, CD274 is linked to non-small cell lung carcinoma.